Randomized, Open Label, 2-way Crossover, Single Dose Bioequivalence Study of Paroxetine IR Tablets Manufactured in GSKT and Mississauga Sites in Healthy Chinese Participants Under Fasting and Fed Conditions
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Paroxetine (Primary)
- Indications Depressive disorders; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 12 Mar 2018 Planned End Date changed from 9 Sep 2018 to 2 Sep 2018.
- 12 Mar 2018 Planned primary completion date changed from 9 Sep 2018 to 2 Sep 2018.
- 12 Mar 2018 Planned initiation date changed from 6 Jun 2018 to 30 May 2018.